Passumpsic Savings Bank Takes $3.14 Million Position in Boston Scientific Corporation $BSX

Passumpsic Savings Bank purchased a new stake in shares of Boston Scientific Corporation (NYSE:BSX) during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 32,941 shares of the medical equipment provider’s stock, valued at approximately $3,141,000. Boston Scientific makes up about 1.7% of Passumpsic Savings Bank’s investment portfolio, making the stock its 19th biggest position.

A number of other hedge funds have also recently made changes to their positions in BSX. Murphy & Mullick Capital Management Corp boosted its stake in shares of Boston Scientific by 200.0% during the third quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock valued at $25,000 after purchasing an additional 170 shares in the last quarter. FWL Investment Management LLC bought a new position in shares of Boston Scientific during the second quarter worth about $26,000. United Community Bank raised its position in shares of Boston Scientific by 115.7% during the third quarter. United Community Bank now owns 274 shares of the medical equipment provider’s stock worth $27,000 after acquiring an additional 147 shares during the last quarter. Colonial Trust Co SC raised its position in shares of Boston Scientific by 502.2% during the third quarter. Colonial Trust Co SC now owns 277 shares of the medical equipment provider’s stock worth $27,000 after acquiring an additional 231 shares during the last quarter. Finally, Bangor Savings Bank raised its position in shares of Boston Scientific by 94.7% during the fourth quarter. Bangor Savings Bank now owns 292 shares of the medical equipment provider’s stock worth $28,000 after acquiring an additional 142 shares during the last quarter. 89.07% of the stock is owned by institutional investors and hedge funds.

Boston Scientific Stock Performance

Shares of NYSE BSX opened at $52.67 on Monday. The stock has a market cap of $78.27 billion, a price-to-earnings ratio of 22.04, a P/E/G ratio of 0.97 and a beta of 0.62. The company has a current ratio of 1.90, a quick ratio of 1.22 and a debt-to-equity ratio of 0.42. Boston Scientific Corporation has a 1-year low of $52.52 and a 1-year high of $109.50. The stock’s 50-day moving average is $63.40 and its 200 day moving average is $81.65.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share for the quarter, beating analysts’ consensus estimates of $0.79 by $0.01. The company had revenue of $5.20 billion for the quarter, compared to analysts’ expectations of $5.19 billion. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.Boston Scientific’s revenue for the quarter was up 11.6% compared to the same quarter last year. During the same period last year, the firm posted $0.75 EPS. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. On average, sell-side analysts anticipate that Boston Scientific Corporation will post 3.38 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the company. Barclays lowered their price objective on Boston Scientific from $124.00 to $96.00 and set an “overweight” rating for the company in a research report on Thursday, April 23rd. JPMorgan Chase & Co. lowered their price objective on Boston Scientific from $135.00 to $100.00 and set an “overweight” rating for the company in a research report on Thursday, February 5th. Needham & Company LLC lowered their target price on Boston Scientific from $97.00 to $77.00 and set a “buy” rating for the company in a report on Thursday, April 23rd. Canaccord Genuity Group dropped their price target on Boston Scientific from $109.00 to $71.00 and set a “buy” rating on the stock in a research report on Thursday, April 23rd. Finally, Royal Bank Of Canada dropped their price objective on Boston Scientific from $105.00 to $100.00 and set an “outperform” rating on the stock in a report on Thursday, April 23rd. One analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat, Boston Scientific presently has a consensus rating of “Moderate Buy” and an average target price of $93.91.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.